Effectiveness of Smartphone Applications vs Conventional Care in Warfarin Therapy: A Randomized Controlled Trial on the Time in the Therapeutic Range
6
Issued Date
2024-01-01
Resource Type
eISSN
22288082
Scopus ID
2-s2.0-85200320945
Journal Title
Siriraj Medical Journal
Volume
76
Issue
7
Start Page
444
End Page
453
Rights Holder(s)
SCOPUS
Bibliographic Citation
Siriraj Medical Journal Vol.76 No.7 (2024) , 444-453
Suggested Citation
Wongkornrat W., Siriussawakul A., Suraarunsumrit P., Charoenrat T., Satidwongpibool T. Effectiveness of Smartphone Applications vs Conventional Care in Warfarin Therapy: A Randomized Controlled Trial on the Time in the Therapeutic Range. Siriraj Medical Journal Vol.76 No.7 (2024) , 444-453. 453. doi:10.33192/SMJ.V76I7.268122 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/100432
Title
Effectiveness of Smartphone Applications vs Conventional Care in Warfarin Therapy: A Randomized Controlled Trial on the Time in the Therapeutic Range
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: Warfarin is extensively used as an oral anticoagulant; however, its clinical application is complicated by a narrow therapeutic index. This investigation evaluated the efficacy of a drug reminder application versus traditional care in facilitating patients’ maintenance of the therapeutic range, as well as in stabilizing the time in the therapeutic range (TTR). Materials and Methods: This was a single-blind randomized controlled trial. Eligible participants were patients receiving warfarin therapy for at least 3 months and demonstrating at least two consecutive international normalized ratio (INR) values within the therapeutic range of 2 to 3 during the preceding 6 months. Patients in the intervention group were provided with a smartphone-based drug reminder application. All participant INRs were collected for 6 months. The outcome measures were TTR, INR, TTR of drug‒drug interactions, and warfarin-related complications. Results: Forty patients were recruited between January 2021 and August 2023. The mean TTR was 66.11%±9.8% for the intervention group and 67.31%±18.08% for the control group. With analysis of covariance, the results were slightly better in the intervention group, but the differences were not statistically significant (95%CI = -5.67 – 1.92, P-value = 0.323). For the 6-month INR monitoring, 6 out of 8 patients who could maintain the therapeutic INR range were in the intervention group. There were no statistically significant differences in warfarin-related complications between the two groups (20% vs 15%, RR 1.333, 95%CI = 0.3413 – 5.2086, P-value = 0.6790). Conclusion: The drug reminder application likely improved the TTR, although without statistical significance. Further studies are needed to identify technology assistance in improving treatment outcomes.